# Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea

> **NCT00455858** · PHASE4 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 87 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** insulin detemir

## Key facts

- **NCT ID:** NCT00455858
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2024-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00455858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00455858, "Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea". Retrieved via MORVS 2026-11-03 from https://api.morvs.ai/clinical/NCT00455858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*